Clarity Medical Group Holding Limited (the “Company”) provided an update on its ongoing resumption process following announcements dated 30 May 2025, 30 June 2025, and 14 January 2026. The Company is required under the Stock Exchange’s Resumption Guidance to conduct an independent forensic investigation into allegations of material misstatements in its Prospectus, assess potential impacts on business operations and financial position, and take appropriate remedial actions.

The Board approved the Separate Special Committee’s recommendation to appoint Grant Thornton Advisory Services Limited as the forensic advisor. Grant Thornton Advisory Services Limited will examine the relevant allegations and present findings to the Separate Special Committee and the Board. The Company intends to release further announcements on the investigation and any resulting actions.

Trading of the Company’s shares has been suspended since 15 April 2025, and this suspension remains in effect until further notice. Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities.